Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | AANAT | Q16613 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.57 |
| ▸ | CCND1 | P24385 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059105 | 0.89 | MEN1 (0.73) | MEN1KMT2ATSHRLMNACYP1A2 | |
| Nb-Acetyltryptamine SCHEMBL468850 | 0.82 | MEN1 (1.00) | MEN1KMT2ATSHRLMNACYP1A2 | |
| SCHEMBL19889081 | 0.81 | MEN1 (0.68) | MEN1KMT2ATSHRLMNACYP1A2 | |
| Nb-Acetyltryptamine SCHEMBL29669230 | 0.80 | MEN1 (0.97) | MEN1KMT2ATSHRLMNACYP1A2 | |
| SCHEMBL6394942 | 0.80 | MEN1 (0.76) | MEN1KMT2ATSHRLMNACYP1A2 | |
| SCHEMBL27488694 | 0.79 | SIRT2 (0.74) | MEN1KMT2ATSHRLMNACYP1A2 | |
| SCHEMBL13560874 | 0.79 | CYP1A2 (0.60) | MEN1KMT2ATSHRLMNACYP1A2 | |
| SCHEMBL27488695 | 0.79 | SIRT2 (0.74) | MEN1KMT2ATSHRLMNACYP1A2 | |
| SCHEMBL13609793 | 0.78 | MEN1 (0.77) | MEN1KMT2ATSHRLMNACYP1A2 | |
| SCHEMBL4331421 | 0.77 | MEN1 (1.00) | MEN1KMT2ATSHRLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | SCARB1, MSR1, HAVCR2 | MEN1 4511/4885KMT2A 4757/4885TSHR 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.